Medicare Coverage for Rheumatoid Arthritis: 2025 Guide
Rheumatoid arthritis affects about 1.5 million Americans, and the biologic medications that control it are among the most expensive drugs in Medicare — often $20,000–$40,000 per year at list price. The 2025 $2,000 annual out-of-pocket cap on Part D drug spending is the most transformative change for RA patients in Medicare's history. Here's what's covered, what it costs, and how to minimize your out-of-pocket expenses.
Rheumatoid Arthritis Coverage Quick Reference
| Service | Part | Your Cost (2025) | Notes |
|---|---|---|---|
| Rheumatologist visits | Part B | 20% after $257 deductible | Specialist management and monitoring |
| Infused biologics (Remicade, Actemra IV, Orencia IV) | Part B | 20% after deductible | Physician-administered IV infusions; covered under Part B |
| Rituximab (Rituxan) infusion | Part B | 20% after deductible | IV infusion for RA and other conditions |
| Subcutaneous/self-injected biologics (Humira, Enbrel, Cimzia, etc.) | Part D | Up to $2,000/year OOP cap | Self-injected; covered under Part D, not Part B |
| JAK inhibitors (Xeljanz, Olumiant, Rinvoq) | Part D | Up to $2,000/year OOP cap | Oral small-molecule drugs; Part D coverage |
| Biosimilars (Hadlima, Hyrimoz, Cyltezo for adalimumab) | Part D | Lower than originator; OOP cap applies | FDA-approved adalimumab biosimilars; growing formulary presence |
| Methotrexate (oral) | Part D | Tier 1 (generic); usually <$10/month | First-line DMARD; very inexpensive generic |
| Hydroxychloroquine (Plaquenil) | Part D | Tier 1 (generic) | DMARD; inexpensive |
| Leflunomide (Arava) | Part D | Tier 1–2 (generic) | DMARD alternative to methotrexate |
| Oral prednisone/steroids | Part D | Tier 1 (generic); very low cost | Short-term flare management |
| Joint X-rays, MRI, ultrasound | Part B | 20% after deductible | Disease monitoring and flare assessment |
| Lab work (CBC, CMP, RF, anti-CCP, CRP, ESR) | Part B | 20% after deductible | Routine monitoring required for RA medications |
| Joint injections (corticosteroid) | Part B | 20% after deductible | Physician-administered intra-articular injections |
| Occupational therapy | Part B | 20% after deductible | Joint protection, adaptive equipment, ADL training |
| Physical therapy | Part B | 20% after deductible | Strength, flexibility, function; no hard annual cap |
| Assistive devices (splints, braces) | Part B (DME) | 20% after deductible | Wrist splints, knee braces when medically necessary |
| Pneumococcal, flu, shingles vaccines | Part B/D (preventive) | $0 for most | Critical — some biologics increase infection risk |
The Most Important Distinction: Part B vs. Part D Biologics
How a biologic is administered determines which part of Medicare covers it — and the cost implications are significant.
Infused Biologics → Part B
Biologics administered by IV infusion in a physician's office or infusion center fall under Part B:
- Infliximab (Remicade) — IV infusion every 4–8 weeks
- Tocilizumab (Actemra) — IV formulation administered in office
- Abatacept (Orencia) — IV formulation
- Rituximab (Rituxan) — IV infusion
You pay 20% of the Medicare-approved amount. For a Remicade infusion that costs $3,000–$5,000, your 20% share is $600–$1,000 per infusion (typically 6–8 times per year). Medigap Plan G covers this 20%, making infused biologics effectively free after the Part B deductible.
Self-Injected Biologics → Part D
Biologics you inject yourself at home fall under Part D prescription drug coverage:
- Adalimumab (Humira) and its biosimilars (Hadlima, Hyrimoz, Cyltezo, and others)
- Etanercept (Enbrel) and biosimilar (Erelzi, Eticovo)
- Certolizumab (Cimzia)
- Golimumab subcutaneous (Simponi)
- Tocilizumab subcutaneous (Actemra SC)
- Abatacept subcutaneous (Orencia SC)
- Sarilumab (Kevzara)
- Secukinumab (Cosentyx)
Under Part D, the 2025 $2,000 annual OOP cap applies. Before 2025, Part D biologic users could face $5,000–$10,000+ in annual drug costs in the catastrophic phase. That cap is now eliminated.
The $2,000 Part D Cap: What It Means for RA Patients
Prior to 2025, a Medicare beneficiary taking Humira (adalimumab) at ~$25,000/year in drug costs would have paid roughly:
- $0 deductible phase (first $590): covered by plan
- Initial coverage phase: ~$590–$5,030 — patient pays 25%
- Catastrophic phase: $5,030+ — patient pays 5% of remaining costs
- Total annual OOP: roughly $3,000–$4,000+
In 2025, the total OOP is capped at $2,000 — regardless of total drug costs. For a patient on a $25,000/year biologic, this is a savings of $1,000–$2,000+ annually.
Also new in 2025: Medicare Prescription Payment Plan (M3P) — allows you to spread your $2,000 OOP cost over monthly installments throughout the year, rather than paying it all early in the year when expensive drugs first hit the coverage stages. This helps with cash flow for patients who get expensive biologics early in the calendar year.
Biosimilar Expansion for RA: Growing Options
Adalimumab (Humira) biologics patents expired in 2023, leading to an expansion of FDA-approved biosimilars. Multiple adalimumab biosimilars are now available and being added to Part D formularies:
- Hadlima (adalimumab-bwwd)
- Hyrimoz (adalimumab-adaz)
- Cyltezo (adalimumab-adbm) — first interchangeable biosimilar
- Yusimry, Hulio, Abrilada, and others
Biosimilars are typically placed at lower tiers on Part D formularies, potentially reducing cost-sharing. However, with the $2,000 OOP cap, the financial difference between Humira and its biosimilars matters less for Medicare beneficiaries than it did previously.
Choosing the Right Medicare Plan for RA
For Patients on Infused Biologics (Part B drugs)
Medigap Plan G is the optimal choice. It covers the 20% Part B coinsurance on IV infusions, making biologic infusions essentially free beyond the $257 Part B deductible. Without Medigap, a patient getting Remicade 6x/year at $4,000/infusion would pay $4,800 in 20% coinsurance annually.
For Patients on Self-Injected Biologics (Part D drugs)
The 2025 $2,000 OOP cap applies regardless of Medigap plan. Your focus should be on selecting the right Part D plan:
- Compare plans specifically for your biologic on Medicare's Plan Finder tool
- Check which formulary tier your drug and its biosimilars are placed at
- Look for plans that place adalimumab biosimilars on preferred tiers
- Consider Extra Help (Low Income Subsidy) if you qualify — it can further reduce your drug costs below the $2,000 cap
Medicare Advantage for RA Patients
Medicare Advantage plans may offer extra benefits (dental, vision) but RA patients should carefully evaluate:
- Whether your rheumatologist is in-network
- Prior authorization requirements for biologics (many MA plans require this)
- Step therapy requirements that force you to try less expensive drugs before covering your prescribed biologic
- Network restrictions on infusion centers
For patients with complex RA on established biologic therapy, Medigap + Original Medicare often provides more predictable access than MA plans with prior authorization hurdles.
Vaccinations: Critical for Immunocompromised RA Patients
Many RA biologics and JAK inhibitors suppress the immune system, making vaccinations particularly important — and some vaccines must be given BEFORE starting immunosuppressive therapy:
| Vaccine | Coverage | RA Consideration |
|---|---|---|
| Pneumococcal (Prevnar 20 or series) | Part B — $0 | High priority; pneumonia risk elevated on biologics |
| Flu vaccine (annual) | Part B — $0 | Annual; critical; inactivated vaccine safe on biologics |
| Shingles (Shingrix) | Part D — usually $0 | Ideally before starting JAK inhibitors or biologics |
| COVID-19 (annual booster) | Part B — $0 | Recommended for immunocompromised patients |
Note: Live vaccines (like older shingles vaccine Zostavax, now discontinued) cannot be given while on biologic therapy. Shingrix is a recombinant vaccine and is safe for most RA patients on biologics — but confirm with your rheumatologist.
Frequently Asked Questions
Yes. Humira (adalimumab) and its FDA-approved biosimilars are covered under Medicare Part D as self-injected medications. In 2025, Part D out-of-pocket drug costs are capped at $2,000 per year — regardless of Humira's list price (~$25,000/year). You can also spread your OOP costs over monthly payments through the Medicare Prescription Payment Plan. Compare Part D plans during the Annual Election Period for the best formulary placement on adalimumab products.
Yes. Remicade (infliximab) is an IV infusion administered in a physician's office or infusion center, so it is covered under Medicare Part B — not Part D. You pay 20% of the Medicare-approved amount after the $257 Part B deductible. Medigap Plan G covers that 20%, making Remicade infusions essentially free for Plan G holders. Without Medigap, 20% of Remicade costs can be significant — potentially $3,000–$5,000/year in coinsurance.
It depends on whether your biologic is infused (Part B) or self-injected (Part D). For infused biologics like Remicade or IV Actemra, Medigap Plan G is the best choice — it covers the 20% Part B coinsurance, making infusions free after the deductible. For self-injected biologics like Humira or Enbrel, Original Medicare + a good Part D plan gives you the $2,000 OOP cap and avoids Medicare Advantage prior authorization hurdles. Patients who are well-established on effective biologic therapy typically do better with Original Medicare + Medigap than with Medicare Advantage plans that impose step therapy or prior authorization for biologics.